ENDRA Life Sciences Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$5.8M | -$10.8M | -$10.5M | -$13.2M | -$11.5M |
| Operating expenses | $5.8M | $10.8M | $10.5M | $13.2M | $11.5M |
| Cash from operations | -$5.2M | -$7.4M | -$9.5M | -$12.8M | -$11.1M |
| Capital expenditure | $17,280 | $16,000 | $33,884 | $202,577 | $45,000 |
| Free cash flow | -$5.2M | -$7.4M | -$9.6M | -$13.0M | -$11.2M |
| Total assets | $3.9M | $4.5M | $6.8M | $9.3M | $12.9M |
| Total liabilities | $1.6M | $1.9M | $1.1M | $2.1M | $2.1M |
Shares outstanding 1.3M · Free float 78.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.